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The remnant kidney model in C57BL/6 mice does not develop
progressive chronic kidney disease (CKD). In this study we
modified the model to mimic features of human CKD and to
define accelerants of disease progression using three strains of
mice. Following the procedure, there was a progressive increase
in albuminuria, progressive loss in renal function, severe
glomerulosclerosis and interstitial fibrosis, hypertension, cardiac
fibrosis, and anemia by 4 weeks in CD-1mice and by 12 weeks in
129S3 mice. In contrast, even after 16 weeks, the C57BL/6 mice
with a remnant kidney had modestly increased albuminuria
without increased blood pressure and without developing CKD
or cardiac fibrosis. The baseline blood pressure, determined by
radiotelemetry in conscious animals, correlated with CKD
progression rates in each strain. Administering angiotensin II
overcame the resistance of C57BL/6 mice to CKD following renal
mass reduction, displaying high blood pressure and albuminuria,
severe glomerulosclerosis, and loss of renal function by 4 weeks.
Decreasing blood pressure with olmesartan, but not hydralazine,
in CD-1 mice with a remnant kidney reduced CKD progression
and cardiac fibrosis. C57BL/6 mice with a remnant kidney and
DOCA–salt hypertension developed modest CKD. Each strain had
similar degrees of interstitial fibrosis in three different
normotensive models of renal fibrosis. Thus, reducing renal mass
in CD-1 or 129S3 mice mimics many features of human CKD.
Angiotensin II can convert the C57BL/6 strain from CKD resistant
to susceptible in this disease model.
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Chronic kidney disease (CKD), the progressive worsening of
kidney function, leads to end-stage renal failure and death.1,2
The 2 million end-stage renal disease patients by 2010 places
a substantial burden on global health-care delivery systems.3
The prevalence of CKD in the United States in 2003 was 11%
(19.2 million)4 with 430% increase over the past decade.5
The major causes of CKD are diabetes and hypertension, but
rodent models of these systemic diseases do not fully replicate
the renal manifestations seen in CKD.6 Typical clinical
characteristics of CKD include decreased glomerular filtra-
tion rate (GFR), proteinuria, glomerulosclerosis and inter-
stitial fibrosis, anemia, and hyperphosphatemia.7 The widely
used remnant kidney model develops progressive CKD in
rats, but mice are relatively resistant to remnant kidney-
induced CKD.8–10 This model not only directly mimics less
prevalent CKD risk factors of surgical renal mass reduc-
tion9,11 and low nephron number due to premature
birth,12–14 but also mimics some aspects of human progres-
sive CKD. A mouse model for CKD would be very useful, as
forward and reverse genetics can be applied to definitively
study pathophysiology,15–18 and rapid breeding of genetically
altered mice would enable the systematic study of multiple
interacting genes.
We were originally interested in CKD as a risk factor and
accelerant of sepsis-induced kidney disease, and used a folic
acid model, which results in extensive fibrosis after recovery
from the acute kidney injury event,19 to simulate CKD.
However, the folic acid model does not have many of the
hallmarks of CKD,20 including glomerulosclerosis, irrever-
sible progression, hypertension, and anemia. Therefore,
we sought a more classic CKD model in mice, such as 5/6
nephrectomy (5/6 Nx).
Several surgical techniques have been used to remove
approximately 5/6 of the renal mass, typically employing
reduction of 1/3 of the renal mass by anterior21 or posterior
renal artery branch ligation22 or kidney pole resection23 in
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concert with uninephrectomy. Ma and Fogo22 demonstrated
that following 5/6 Nx, the mostly inbred 129Sv strain but not
the inbred C57BL/6 strain develops glomerulosclerosis and
hypertension. A hybrid electrocautery–uninephrectomy mod-
el has been established in the outbred CD-1 strain24 and the
nearly inbred 129Sv strain25 for uremic cardiomyopathy;
however, characterization of CKD was incomplete. Despite
these recent successes, there are still a limited number of
publications using mouse kidney remnant models. The
difficulty of the surgery, reproducibility, and need for long
follow-up time (9–12 weeks) might be factors limiting the
widespread implementation of this model.8,26
Hypertension is an important risk and progression factor
both clinically27 and in animal models. However, blood
pressure is usually measured by tail cuff method that is
vulnerable to artifacts from mouse manipulation.28 In this
study, we continuously measure conscious blood pressure by
radiotelemetry, which is less susceptible to artifact than tail
cuff blood pressure.29 The 129Sv strain has been widely used
for homologous recombination in embryonic stem cells to
generate knockout mice, but this strain is not genetically
homogeneous, and much ambiguity remains in the literature,
despite a corrected nomenclature in 1999 that describes
substrains that are properly inbred. Therefore, to eliminate
potential artifact from the genetic heterogeneity of the 129Sv
‘strain’, we used 129S3 mice, a defined, stable, inbred
substrain of 129Sv.30 We examined differences between
strains of mice for their sensitivity and resistance to CKD,
and we characterize how well the additional features of each
model correspond to human CKD.
RESULTS
CD-1 and 129S3 but not C57BL/6 mice develop
progressive CKD following 5/6 Nx
We compared the development of renal and extra-renal
manifestations of CKD in three mouse strains after resection
of 2/3 of the left kidney, followed by a right nephrectomy
1 week later (Figure 1). At 1 week after the second surgery,
kidney function was appropriately low following 5/6 Nx in all
three mouse strains (C57BL/6, 129S3, and CD-1 mice), as
determined by increases in blood urea nitrogen (BUN) and
serum creatinine (SCr), but did not change in normal, sham
surgery, or 2/6 Nx control mice (Figure 2a and b). The
increase in SCr progressed fastest in CD-1 mice, more
gradually in 129S3, and remained stable after the initial jump
in C57BL/6 mice, consistent with previous reports in
individual strains.22,23 Reciprocal changes were seen in the
GFR determined in conscious mice (Figure 2c). The GFRs
after 5/6 Nx in C57BL/6 at 10 weeks, in 129S3 at 10 weeks,
and in CD-1 at 4 weeks were 75±4, 48±5, and 54±3ml/min,
respectively (n¼ 4 per group). The average GFR of normal or 2/
6 Nx control in all strains was 431±25ml/min. GFR was
significantly lower in 129S3 and CD-1 than in C57BL/6 mice,
but the differences among strains were rather modest. Urine
albumin excretion, demonstrated by spot urine albumin–crea-
tinine ratio (ACR), dramatically increased more rapidly in CD-1
mice (0, 1, 2, and 4 weeks: 14±2, 108±29, 2919±370, and
3265±379mg/g, respectively, n¼ 8–11 per group) than in 129S3
mice (0, 1, 2, 4, 8, and 12 weeks: 15±2, 82±11, 418±6,
1898±155, 2990±530, and 3488±422mg/g, respectively,
n¼ 8–11 per group; Figure 2d). In contrast, the ACR remained
stable in C57BL/6 mice after 5/6 Nx, the highest value reaching
127±97mg/g (n¼ 9) at 12 weeks but not statistically different
from 0 weeks, normal, or 2/6 Nx control mice (28±7mg/g).
Thus, CD-1 and 129S3 showed strain-dependent susceptibility
to progressive CKD, whereas C57BL/6 mice were resistant.
Induction of 5/6 Nx in susceptible mouse strains caused
mesangial expansion and glomerular fibrosis detected with
periodic acid-Schiff stain and interstitial fibrosis detected
with Masson’s trichrome stain (Figures 3, 4, and Supple-
mentary Figure S1 online). The percentage of glomeruli with
moderate and severe expansion (mesangial expansion
50–80% and 480%) increased rapidly after 5/6 Nx in CD-1
mice at 4 weeks with similar changes achieved in 129S3 mice
within 12 weeks (Figure 4a). In contrast, glomerular damage
was much less severe, without progression, in C57BL/6, even
after 16 weeks. Tubulointerstitial fibrosis also appeared more
rapidly after 5/6 Nx in CD-1 mice compared with 5/6 Nx in
129S3 mice (Figure 4b and Supplementary Figure S1 online).
The progressive morphologic changes (glomerular injury and
interstitial fibrosis) were more tightly associated with progres-
sive albuminuria than with the decline in kidney function.
Strain-selective differences in baseline mean arterial
pressure and progressive hypertension following 5/6 Nx
Elevated systemic blood pressure is a risk factor for CKD and
exacerbates progression in humans and rodents. We mea-
sured changes in conscious blood pressure by radiotelemetry,
using a catheter in the carotid artery. The baseline mean
arterial pressure (MAP) in CD-1 and 129S3 was significantly
higher than in C57BL/6 mice (133±3, 119±7, and
100±4mmHg, respectively; Figure 5a and b); in contrast,
baseline renin activity was not significantly different
(Supplementary Figure S2 online). All three strains exhibited
similar circadian variations, with daytime dipping of blood
pressure during sleep (Figure 5a). After 5/6 Nx, MAP in
week–1
Resect upper and lower
poles of left kidney (W1)
Rt. nephrectomy (W2)
(    = Sampling / measuring)
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Ratio (W1/W2)
> 0.55
week1 week2 week4 week8 week12
Figure 1 | Two-stage reduction in renal mass model (5/6 nephrectomy). Schema of mouse 5/6 nephrectomy protocol. Animals were
studied if the ratio of resected left kidney/removed right kidney (W1/W2; see Materials and Methods) was 0.55–0.72.
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CD-1 and 129S3 mice increased progressively as early as 2
weeks after surgery, and the differences in MAP between all
three strains expanded over time (Po0.0001; Figure 5b–d).
In contrast, the MAP in C57BL/6 was only moderately
elevated 1 week after 5/6 Nx, and then stabilized (Figure 5b
and e). As a result, the MAP in CD-1 and 129S3 strains, even
baseline values, were higher than C57BL/6 at every time
point. The circadian variation (daytime dipping during sleep)
was not altered by 5/6 Nx (Figure 5a, c–e).
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Figure 2 | Strain-specific temporal changes in kidney function
and albuminuria following reduction of renal mass. Time
course of renal function as determined by (a) blood urea nitrogen
(BUN) or (b) serum creatinine (SCr) and albuminuria as determined
by spot urine albumin–creatinine ratio (ACR) (d) in composite
normal control (n¼ 6), composite 2/6 nephrectomy (Nx) control
(n¼ 6), 5/6 Nx in C57BL/6 (n¼ 5–9), 129S3 (n¼ 5–11), and CD-1
(n¼ 5–12) strains. The (c) glomerular filtration rate (GFR) of
C57BL/6, 129S3 at week 10 and CD-1 at week 4 with normal sham
surgery control, 2/6 Nx control, and 5/6 Nx (n¼ 4 per group).
*Po0.05 5/6 Nx in CD-1 vs C57BL/6; #Po0.05 5/6 Nx in 129S3 vs
C57BL/6; þPo0.005 5/6 Nx in CD-1 vs 129S3 in the same time
point; yPo0.001 urine ACR at specific time point vs week 0;
yyPo0.05 urine ACR at specific time point vs week 0.
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Figure 3 | Strain-specific changes in glomerular injury
following reduction in renal mass. Representative images of
sections stained by periodic acid-Schiff (PAS) (left panels) and
Masson’s trichrome (right panels) after 5/6 nephrectomy (5/6 Nx)
in (a) C57BL/G at week 16, (b) 129S3 at week 12, and (c) CD-1 at
week 4 (original magnification  400).
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Figure 4 | Strain-specific changes in glomerular injury and tubulointerstitial fibrosis following reduction in renal mass.
Semiquantitative measures of glomerular injury assessed by mesangial expansion (a) in periodic acid-Schiff stain (upper panel, original
magnification  400) and tubulointerstitial fibrosis score (b) from Masson’s trichrome stain of composite normal control at week 16 (n¼ 5),
composite 2/6 nephrectomy (Nx) at week 16 (n¼ 5), 5/6 Nx in C57BL/6 at week 4 (n¼ 4) and week 16 (n¼ 8), 5/6 Nx in 129S3 at week 4
(n¼ 5) and week 12 (n¼ 7), and 5/6 Nx in CD-1 at week 4 (n¼ 10). See Materials and Methods section for details. *Po0.05 5/6 Nx in CD-1
week 4 vs 129S3 week 4.
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Angiotensin II (Ang II) administration induces hypertension
and rapid progression of CKD in CKD-resistant C57BL/6 mice
As the strain specificity of blood pressure and CKD
progression (including proteinuria and histological changes)
were similar, we sought to determine the impact of blood
pressure on the progression of CKD. We increased blood
pressure in CKD-resistant C57BL/6 mice, and used anti-
hypertensive treatment in CKD-susceptible CD-1 mice. Ang
II infusion induces hypertension in experimental ani-
mals,31,32 and increases CKD progression in the rat 5/6 Nx
model,33 although it not been studied in mice after 5/6 Nx.
Infusion of Ang II by osmotic minipump (0.75 mg/kg/min)
increased blood pressure in both normal and 5/6 Nx C57BL/6
mice within 1 week (Figure 6a and b); by 4 weeks the blood
pressure had risen by 69±6 and 52±5mmHg (Figure 6b).
Ang II infusion rapidly induced albuminuria within 1 week in
both 5/6 Nx and sham surgery control mice, although the
ACR was 15-fold higher in the 5/6 Nx group throughout the
4 weeks of administration (Figure 6c). Daily (24 h) albumin
excretion was similarly increased by ninefold (shamþ vehicle:
70±9mg/day; shamþAng II: 579±79; 5/6 Nxþ vehicle:
493±113; and 5/6 NxþAng II: 4830±382; Figure 6c and d).
Ang II further reduced kidney function as measured by
elevated BUN and SCr and decreased GFR (Figure 6f and g)
and caused glomerular and tubular injury (Figure 7a–d) in
mice subjected to 5/6 Nx but not in sham controls. Ang II
infusion also caused other signs of CKD including polyuria
(Figure 6e).
After a short-term (2 weeks) administration of Ang II,
albuminuria and histological damage was still present even
2 weeks after discontinuation of Ang II (data not shown),
consistent with a durable, irreversible effect. In summary, the
C57BL/6 resistance to CKD could be only overcome by the
combination of reduced kidney mass and Ang II-induced
hypertension.
Olmesartan treatment slows progression of CKD in a
susceptible mouse strain, CD-1
Diet-administered olmesartan, an Ang II type I receptor
antagonist, gradually reduced blood pressure in sham-treated
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Figure 5 | Strain-specific changes in diurnal and temporal
mean arterial pressure (MAP) by telemetry after reduction in
renal mass. Systemic blood pressure measured by telemetry.
Diurnal changes in (a) baseline MAP (n¼ 11–13 per group),
(b) temporal changes in MAP following 5/6 Nx (n¼ 4 to
5 per group), and (c–e) diurnal changes in MAP following 5/6
nephrectomy (Nx) in C57BL/6, 129S3, and CD-1 mice (n¼ 4 to
5 per group). Black bars indicate nighttime. *Po0.001 CD-1 vs
C57BL/6; **Po0.05 CD-1 vs C57BL/6; #Po0.005 129S3 vs C57BL/6;
##Po0.05 129S3 vs C57BL/6; þPo0.05 CD-1 vs 129S3; wPo0.001
MAP at specific time point vs baseline; wwPo0.05 MAP at specific
time point vs baseline MAP of CD-1 5/6 nephrectomy at week 1, 2,
and 4 were 134±8, 154±9, and 171±7mmHg; MAP of 129S3
5/6 Nx at week 1, 2, 4, 8, and 12 were 117±3, 124±3, 150±6,
161±10, and 168±11mmHg; and MAP of C57BL/6 at week 1, 2,
4, 8, and 12 were 110±6, 109±7, 107±4, 107±4, and
108±5mmHg, respectively (Figure 6b). By repeated measures
analysis of variance (ANOVA) blood pressure change over time at
weeks 1, 2, and 4, within-subject effect (time) is significant
(Po0.0001) and interaction between time and strain is significant
(P¼ 0.0008). Therefore, the between-strain differences in mean
blood pressure were expanding from weeks 1 to 4.
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and 5/6 nephrectomized CD-1 mice (Figure 8a) by 31±3 and
34±2mmHg, respectively; the latter was still 19mmHg
higher than in the sham surgery group (Figure 8b).
Olmesartan dramatically blunted the 5/6 Nx-induced in-
crease in ACR even within 1 week; after 4 weeks, the 24 h
albumin excretion was reduced by 92% (316±79 and
4071±847 mg/day in the olmesartan and vehicle groups,
respectively; Figure 8c and d). Olmesartan also attenuated
polyuria (Figure 8e), progressive loss in kidney function
(measured by BUN, creatinine, and GFR; Figure 8f and g),
and progressive glomerular and tubular injury (Figure 8h and i).
Thus, in every renal manifestation of CKD that we measured,
olmesartan reduced the severity of CKD induced by 5/6 Nx in a
susceptible strain (CD-1).
DOCA–salt does not sensitize C57BL/6 mice to 5/6 Nx-induced
CKD, and hydralazine does not desensitize CD-1 mice to
5/6 Nx-induced CKD
Because Ang II could also confer sensitivity of C57BL/6 mice
to 5/6Nx-induced CKD, we also tested deoxycorticosterone
acetate combined with saline drinking water (DOCA–salt),
which elevated MAP to the same extent as Ang II (Figure 9a;
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Figure 8 | Effect of olmesartan treatment on blood pressure, renal function, and injury in CD-1 mice after reduction in renal mass.
(a) Mean arterial pressure (MAP) change of CD-1 mice following 5/6 Nx or sham surgery controls (sham) with olmesartan treatment or
placebo control. The response to olmesartan of the sham surgery (control) and 2/6 Nx sham surgery was not different, and hence the data
were combined (Sham Olm). Effect of olmesartan or placebo control on (b) MAP at week 4, (c) increase in spot urine albumin–creatinine
ratio (ACR), (d) 24 h urine albumin at week 4, (e) 24 h urine volume at week 4, (f) progression of blood urea nitrogen (BUN) and serum
creatinine (SCr), (g) glomerular filtration rate (GFR) at week 4, and (h, i) semiquantitative scoring of kidney at week 4 subjected to 5/6 Nx or
sham surgery control with olmesartan or placebo (n¼ 4–6 per group). *Po0.005 5/6 Nxþ olmesartan vs 5/6 Nxþ placebo; **Po0.05 5/6
Nxþ olmesartan vs 5/6 Nxþplacebo, #Po0.005 5/6 Nxþ olmesartan vs sham þ olmesartan, ##Po0.05 5/6 Nxþ olmesartan vs sham with
Olm; wPo0.001 value at specific time point vs baseline; wwPo0.05 value at specific time point vs baseline.
Kidney International (2010) 78, 1136–1153 1143
A Leelahavanichkul et al.: Rapid glomerulosclerosis in CD-1 kidney remnant model o r ig ina l a r t i c l e
Supplementary Figure S3 online), but caused only modest
albuminuria (Figure 9b; Supplementary Figure S3 online)
relative to Ang II, consistent with a largely blood pressure-
independent effect of Ang II to convert C57BL/6 mice from
CKD resistant to CKD susceptible after 5/6 Nx.
Conversely, we treated CD-1 mice with hydralazine, which
reduced MAP to the same extent as olmesartan (Figure 9c;
Supplementary Figure S3 online), but did not significantly
reduce 5/6 Nx-induced albuminuria, relative to control; in
contrast, olmesartan decreased albuminuria to levels ap-
proaching those after sham Nx (Figure 9d; Supplementary
Figure S3 online). This further supports a primarily blood
pressure-independent role for Ang II in our 5/6 Nx CKD
model. However, residual hypertension could still have a
significant contribution to CKD.
C57BL/6, 129S3, and CD-1 are equally susceptible to kidney
fibrosis following unilateral ureteral obstruction, folic acid,
and chronic post-ischemic/reperfusion injury
Kidney fibrosis is the result of an exuberant healing process
after inflammation.34 The strain differences in kidney fibrosis
following 5/6 Nx might be caused by differences in the
inflammatory, healing, or fibrotic processes among the three
mouse strains. To determine if the strain sensitivity was
specific to 5/6 Nx or more generalized, we performed other
kidney fibrosis models (unilateral ureteral obstruction
(UUO), folic acid administration (FA), and chronic post-
ischemia/reperfusion with unilateral nephrectomy (Chr I/R))
in these three mouse strains. Surprisingly, the natural history
and severity of kidney fibrosis was strain independent in
these three additional models (Figure 10, Table 1, and
Supplementary Figure S4 online). These findings are
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Figure 9 |Mean arterial pressure (MAP) and albuminuria after deoxycorticosterone acetate combined with saline drinking water
(DOCA–salt) administration/reduction of renal mass in C57BL/6 mice or after hydralazine treatment/reduction of renal mass in
CD-1 mice. (a) MAP and (b) albuminuria 4 weeks after 5/6 nephrectomy (5/6 Nx) or sham surgery controls (sham) in C57BL/6 mice
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consistent with previous studies demonstrating similar
degrees of susceptibility to UUO between C57BL/6 and
129Sv strains.35 As expected, there was normal renal function
in UUO and slow progression of albuminuria, cachexia,
BUN, and SCr in the Chr I/R and FA models (Table 1).
Clinically relevant characteristics of the 5/6 Nx model
of CKD
Weight loss and hyperphosphatemia are common clinical
consequences of CKD.1,2 Normal 7- to 9-week-old mice gain
weight as they grow; in contrast, 129S3 and C57BL/6 mice
did not gain weight, whereas CD-1 mice lost weight after 5/6
Nx (Figure 11a). Control 2/6 Nx mice had a nonsignificant,
transient decrease in body weight after surgery but then
resumed normal growth within 2 weeks. Within 1 week of the
2/6 Nx surgery (both 2/6 Nx and 5/6 Nx groups, 0 weeks),
mice were anemic with corresponding high (410,000-fold
increase) erythropoietin (EPO) levels, reflecting a compensa-
tory increase that occurs clinically within 1 week after acute
anemia.36,37 Mice subjected to only 2/6 Nx were able to
recover from their anemia, with a corresponding return to
baseline EPO levels (Figure 11b and c). All mouse strains
subjected to 5/6 Nx had a further decline in hematocrit after
the right kidney was removed at 0 weeks, and EPO levels
declined precipitously within 1 week, with only a modest
increase at 2 weeks, relative to the progressing anemia. The
rate of development of anemia and hyporesponsiveness of
EPO level paralleled the SCr increase. Mice subjected to 2/6
Nx rapidly resolved their surgical anemia, eventually
returning their transiently elevated EPO levels to normal
(Figure 11c). All three mouse strains developed hyperpho-
sphatemia after 5/6 Nx, although the degree of hyperpho-
Table 1 | Characteristics of kidney fibrosis models: unilateral ureteral obstruction, folic acid, and chronic post-ischemia/
reperfusion injury
BUN (mg/dl) SCr (mg/dl) ACR (lg/mg) Hct (%) EPO (pg/ml) BW (g) Sham BW (g) DBW (g)
UUO (2 weeks)
C57BL/6 20±3 0.16±0.02 26±3 50±2 102±13 24±1 26±1 2±1
129S3 15±2 0.15±0.01 25±3 50±1 91±11 24±1 25±1 1±0.5
CD-1 20±2 0.13±0.01 17±3 50±1 85±12 35±1 38±1 3±1
5/6 Nx (2 weeks)
C57BL/6 58±3* 0.38±0.09w 69±16 36±1w 421±89w 22±1 26±1 4±1#
129S3 73±3* 0.41±0.08* 559±110* 37±1* 386±64w 22±1 25±1 4±1#
CD-1 79±9* 0.49±0.1* 1176±277* 35±2* 91±24 34±2 38±1 4±2#
5/6 Nx (12 weeks) (4 weeks in CD-1)
C57BL/6 58±9* 0.54±0.04* 78±75* 37±1* 98±34 28±1 32±1 4±1#
129S3 83±16* 0.73±0.19* 2545±596w 37±1w 85±36 23±2 31±1 8±1#
CD-1a 79±19* 0.48±0.06* 2640±502* 34±3* 50±24 39±2 41±2 7±4#
FA (2 weeks)
C57BL/6 57±4* 0.61±0.01* 98±10* 39±1* 160±70 24±1 26±1 2±1
129S3 58±5* 0.47±0.04* 80±9* 39±1* 124±45 23±1 26±1 3±1
CD-1 59±9* 0.59±0.06* 89±13* 40±1* 109±65 33±1 36±1 5±1#
FA (12 weeks)
C57BL/6 50±5* 0.59±0.03* 110±24* 45±2w 490±85w 32±1 33±1 1±1
129S3 50±5* 0.49±0.08* 220±36* 39±2* 340±40w 31±1 32±1 1±1
CD-1 50±5* 0.46±0.08* 158±12* 41±2* 290±98w 53±1 56±2 4±1#
Chr I/R (2 weeks)
C57BL/6 64±9* 0.54±0.02* 232±29* 25±1 114±6 24±1 26±1 2±1
129S3 73±10* 0.57±0.04* 112±15* 27±2* 194±9w 23±1 26±1 3±1
CD-1 64±9* 0.54±0.02* 92±12* 25±1* 214±6w 32±1 38±1 5±1#
Chr I/R (12 weeks)
C57BL/6 43±5* 0.66±0.05* 434±118w 34±2 268±28w 30±1 33±1 3±1
129S3 58±9* 0.46±0.04* 644±191w 34±1 272±30w 26±1 31±1 4±1#
CD-1 40±5* 0.62±0.06* 776±91* 35±2* 328±39w 47±2 56±2 8±1#
Abbreviations: 5/6 Nx, 5/6 nephrectomy; ACR, urine albumin–creatinine ratio; BUN, blood urea nitrogen; BW, body weight; Chr I/R, chronic post-ischemia/reperfusion injury
with unilateral nephrectomy; EPO, erythropoietin; FA, folic acid injection; Hct, hematocrit; SCr, serum creatinine; UUO, unilateral ureteral obstruction; DBW, sham BW-model
BW at reciprocal age.
aData from CD-1 5/6 Nx week 4.
Data are mean±s.e.; n=4 per group.
#Po0.05 vs sham.
wPo0.05 vs UUO.
*Po0.005 vs UUO.
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sphatemia was worse in CD-1 and 129S3 strains; amylasemia
was elevated in all three mouse strains, with 129S3 and CD-1
slightly higher than C57BL/6 (Figure 11d). Therefore, several
non-renal manifestations of CKD observed in patients are
replicated in this 5/6 Nx mouse model.
Strain-dependent susceptibility to CKD-induced cardiac
fibrosis is partially dependent on CKD severity and
blood pressure
Cardiac fibrosis developed following 5/6 Nx in both 129S3
mice and, despite the short time frame of 4 weeks, in CD-1
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mice, but not in C57BL/6 mice, even at 16 weeks
(Figure 12a–d). Ang II infusion caused cardiac fibrosis in
C57BL/6 sham surgery mice within 4 weeks (Figure 12e).
Olmesartan treatment of CD-1 mice after 5/6 Nx also
decreased the severity of cardiac fibrosis (Figure 12f). Cardiac
fibrosis was further significantly increased in C57BL/6 mice
subjected to 5/6 Nx and Ang II infusion (Figure 12e,
Supplementary Figure S5 online). Ang II infusion caused
higher MAP in normal mice than in 5/6 Nx mice (Figure 6b);
however, the cardiac fibrosis was more extensive after 5/6 Nx
(Figure 12e), indicating that blood pressure is not the only
determinant of cardiac fibrosis severity.
Global changes in renal architecture visualized ex vivo
by contrast-enhanced microCT
The regional differences in kidney injury were implied upon
histological staining of sections at low magnification
(Supplementary Figure S4 online), but serial sections are
impractical. To complement the detailed, cellular-level view
provided by histology, we used micro-computed tomography
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Figure 12 | Strain-specific changes in cardiac fibrosis after reduction in renal mass and changes in cardiac fibrosis after angiotensin
II (in C57BL/6 resistance strain) or olmesartan (in CD-1 susceptible strain) administration. Typical images of Masson’s trichrome-
stained cardiac sections after 5/6 Nx in (a) C57BL/6 at week 16, (b) 129S3 at week 12, and (c) CD-1 at week 4 (original magnification  20).
(d) The percentage of fibrotic area was more severe in 129S3 5/6 Nx at 12 weeks compared with 5/6 Nx in other strains (n¼ 4 per group).
(e) Angiotensin II administration in either sham normal kidney or 5/6 Nx in C57BL/6 (resistant strain) mice caused mild and severe cardiac
fibrosis, respectively (n¼ 4 per group), (f) olmesartan treatment in CD-1 5/6 Nx attenuated cardiac fibrosis (n¼ 4–6 per group). *Po0.05,
**Po0.001.
Figure 11 | Strain-specific temporal changes in body weight (BW), anemia, erythropoietin (EPO), and serum phosphate following
reduction in renal mass. Temporal changes in (a) BW, (b) hematocrit (Hct), and (c) serum erythropoietin (EPO). Number of animals for body
weight ((CD-1 with normal sham surgery control (n¼ 7), 2/6 Nx control (n¼ 4), and 5/6 Nx (n¼ 12)), (129S3 and C57BL/6 with normal
sham surgery control (n¼ 5), 2/6 Nx control (n¼ 8), 129S3 5/6 Nx (n¼ 12), and C57BL/6 5/6 Nx (n¼ 9))), Hct and serum EPO (composite
normal sham surgery control (n¼ 6), 2/6 Nx control (n¼ 6), CD-1 5/6Nx (n¼ 12), 129 Sv 5/6 Nx (n¼ 12), and C57BL/6 5/6 Nx (n¼ 9)),
(d) serum phosphate and (e) amylase (composite normal sham surgery control at week 16 (n¼ 6), composite 2/6 Nx control at week 16
(n¼ 6), C57BL/6 5/6 Nx at week 16 (n¼ 4), 129S3 5/6 Nx at week 12 (n¼ 4) and CD-1 5/6 Nx at week 4 (n¼ 4)). *Po0.001 CD-1 5/6 Nx vs 2/6
Nx; wPo0.005 5/6 Nx at specific time point vs week 0; wwPo0.05 5/6 Nx at specific time point vs week 0; #Po0.001 5/6 Nx in 129S3 vs
composite 2/6 Nx; ##Po0.005 5/6 Nx in C57BL/6 vs composite 2/6 Nx; þPo0.001 5/6 Nx vs composite 2/6 Nx; þ þPo0.001 composite 2/6
Nx vs normal; þ þ þPo0.05 composite 2/6 Nx vs normal; yPo0.05 5/6 Nx vs composite 2/6 Nx; yyPo0.001 5/6 Nx vs composite 2/6 Nx.
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(microCT) imaging to gain a more global view of kidney
damage in moderate detail to compare some of our models
(Figure 13 and Supplementary Movies S1–S5 online).
Changes in renal structures are difficult to discern in the
original microCT images, but digital rendering with false
coloring of subtle differences in staining revealed gross
changes in morphology. In normal kidneys the surface is
clearly smooth, in contrast to irregular surface of the fibrotic
kidney after folic acid treatment (Figure 13d). The bumpy
surface was more subtle in the chronic post-I/R kidney
(Figure 13e) and bumpy contours were not evident on the
non-resected surfaces of the 5/6 nephrectomized kidney
(Figure 13c), consistent with a lower severity in fibrosis
(Figures 4 and 10). The interior of the kidney also revealed
some striking differences. In the normal kidney, large
branched structures could be traced to the renal pelvis,
indicating a predominant staining of renal-collecting ducts
(Figure 13a, Supplementary Movie S1 online); a stellate
structure in the renal medulla is also visible, only in normal
kidney. Kidneys from the folic acid model (Figure 13d,
Supplementary Movie S2 online) and 2/6 Nx controls (Figure
13b, Supplementary Movie S3 online) were similar in their
largely transparent appearance, lack of fine structure, and
prominence of apparent large branches of collecting ducts,
which were fewer in number, relative to normal (Figure 13a).
The most severely injured kidneys from the 5/6 Nx (Figure
13c, Supplementary Movie S4 online) and chronic post-I/R
(Figure 13e, Supplementary Movie S5 online) models had
very dense staining that corresponds roughly with the level of
albuminuria (Table 1). The density of staining and the non-
contiguous nature of the branched structures made it
impossible to distinguish between vasculature and tubules;
notably absent were clearly visible glomeruli, which would be
useful landmarks to define nephrons. Some spherical staining
can be spotted, especially in kidneys from the chronic post-I/
R model (Supplementary Movie S5 online), but staining of a
truncated vessel or tubule could not be ruled out. Although
regional differences in fibrosis, especially seen in the folic acid
model (Supplementary Figure S4 online), were not directly
reflected in staining of affected areas, these differences
appeared to coincide with the drop-out of staining of major
collecting duct structures.
DISCUSSION
The major findings of this study are: (1) the CD-1 mouse
strain, in response to 5/6 Nx, develops robust CKD within
4 weeks, even faster than the 12 weeks observed for the 129S3
strain that mimics the clinical status of CKD patients, with a
loss of or failure to gain body weight, anemia, and
subsequent loss of EPO response, phosphatemia, and cardiac
fibrosis; (2) baseline and post-5/6 Nx blood pressure,
measured by telemetry in the conscious state, was higher in
CD-1, than in 129S3, and lowest in C57BL/6 strains,
corresponding to susceptibility to CKD; (3) Ang II admin-
istration to the resistant C57BL/6 strain increased suscept-
ibility to CKD after 5/6 Nx; treatment of the susceptible CD-1
strain with olmesartan reduced CKD progression; (4) DOCA–
salt treatment increased blood pressure to the same extent as
Ang II in C57BL/6 mice after 5/6 Nx, but only minimally
increased CKD; hydralazine treatment decreased blood pressure
to the same extent as olmesartan, but did not significantly
decrease CKD, consistent with a substantial role for blood
pressure-independent effects of the renin–angiotensin–aldoster-
one (RAAS) system on the strain-dependent susceptibility to 5/6
Nx-induced CKD; and (5) the three strains had similar
susceptibility to renal interstitial fibrosis in three non-hyperten-
sive fibrosis models, supporting a less important role of intrinsic
fibrogenesis as a cause of the strain differences following 5/6 Nx.
2/6 Nx
5/6 NxNormal
Folic acid Chronic post-I/R
Figure 13 |Three-dimensional rendering of mouse kidney
acquired through microCT-based Virtual Histology from
normal, 5/6 Nx, folic acid injection, and chronic post-I/R.
Renderings from serial microCT sections from CD-1 mice in (a)
sham normal kidney at 4 weeks, (b) left kidney after 2/6 Nx control
at 4 weeks, (c) left kidney after 5/6 Nx at 4 weeks, (d) folic acid
injection after 2 weeks and (e) chronic post-I/R at 12 weeks.
Digital sagittal sections of the three-dimensional image from
sham normal kidney showed smooth surface and clear cortical
area (a), 2/6 Nx control demonstrated mild irregular surface but
clear cortical area (b); in contrast, dense opaque yellow color was
found in 5/6 Nx model (c) reciprocal with very high proteinuria.
The severe irregular surface with clear cortical area in folic acid
model (d) correlated with severe interstitial fibrosis without
albuminuria in this model. Moderately dense yellow color in
cortical area of chronic post-I/R (e) corresponded with moderate
albuminuria.
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Refining the model
The rat 5/6 Nx model replicates many aspects of human
progressive CKD with a uninephrectomy combined with a
simple reduction of 2/6 of the kidney mass by ligation of the
renal artery branches and subsequent infarction,38 whereas
the mouse arterial vascular anatomy makes it technically
difficult to ligate the anterior21 or posterior renal artery
branch23 and also achieve reproducible injury.8 Surface
electrocauterization has similar reproducibility pro-
blems.39–41 Surgical removal of the upper and lower poles
for 2/6 reduction of renal mass causes major hemorrhage,
which is typically stopped by cauterization, a procedure that
requires much skill to perform quickly without causing
extensive damage. We used brief clamping of the renal pedicle
followed by resection and hemostasis with Avitene (Davol,
Cranston, RI).42 Combined with monitoring the extent of
kidney resection (see Materials and Methods), we found this
slightly modified model to be straightforward and reliable.
Indeed, our model mimicked several features of human CKD:
weight loss/lack of weight gain, anemia, loss of EPO response
to anemia, and hyperphosphatemia. The severity of all
parameters, except for hematocrit/EPO and cardiac fibrosis,
reflected the strain dependence of CKD progression. The
129S3 strain, which displayed intermediate CKD severity by
all other respects (hypertension, proteinuria, glomerulo-
sclerosis, and so on), had a slower onset of anemia than the
CKD-resistant C57BL/6 strain but more rapid cardiac fibrosis
than the CD-1 strain despite having an intermediate level
of hypertension.43–47 This observation may be a consequence
of longer survival relative to the CD-1 strain that allows the
129S3 strain to develop more extensive cardiac fibrosis.
Alternatively, there could be non-renal secondary effects of
CKD and/or strain-dependent susceptibility of cardiac fibrosis.
Strain-dependent susceptibility to CKD and progression of
CKD: correlation with blood pressure
The three strains of mice, CD-1, 129S3, and C57BL/6, had
different susceptibility to CKD; as expected, the strain-
specific progressive loss of renal clearance closely paralleled
the degree of proteinuria, glomerulosclerosis, and tubuloin-
terstitial fibrosis as seen clinically.48 Hypertension is a
dominant risk factor and accelerant in CKD patients.49,50
Reduction in ambulatory blood pressure beyond that because
of RAAS inhibition reduced CKD progression in children.51
In a previous study of strain-dependent susceptibility by Ma
and Fogo,22 the researchers demonstrated that conscious
blood pressure, measured by tail cuff, became elevated after
5/6 Nx in the CKD-prone 129Sv strain, whereas blood
pressure was unchanged in the CKD-resistant C57BL/6
strain. They also found the outbred Swiss-Webster strain to
be susceptible to CKD, but did not measure blood pressure;
baseline blood pressures for 129Sv appeared to be slightly
higher than for C57BL/6, but not significant. These data
are confounded by the unexpected genetic heterogeneity of
the 129Sv strain.30 In another study, there was no difference
in baseline conscious blood pressure (measured by tethered
catheter) between Swiss-Webster and C57BL/6 mice.52
Additional technical reasons may explain these inconsisten-
cies, unless blood pressure is not as important in the mouse
5/6 Nx model as it is in the rat model.53 Telemetry appears to
be the most definitive method for conscious blood pressure,54
as handling of mice for tail cuff measurements can cause
stress-related hypertension,53 and conscious blood pressure
measurements by tail cuff have known discrepancies with
indwelling catheters55 and telemetry.29
Our telemetry data demonstrate that differences between
baseline blood pressure in the three strains correspond to
their susceptibility to CKD progression, and that blood
pressure further increase during progression in the sensitive
strains, without an increase in blood pressure in the resistant
C57BL/6 strain. The telemetry data further documented that
strain-dependent differences in blood pressure persisted
throughout the day, unlike the 17% of human subjects with
CKD who are classified as non-dippers by ambulatory blood
pressure measurements.56 Because hypertension, glomerulo-
sclerosis, proteinuria, and interstitial fibrosis are temporally
overlapping and have complex manifestations, it is difficult
to distinguish their pathophysiological hierarchy without
perturbing the system. We first took advantage of the
remarkable resistance of the C57BL/6 to CKD, especially
considering that there is no progression even within the
microalbuminuric range.
Ang II as a critical factor for susceptibility to CKD progression
The RAAS system has a major impact on the regulation of
blood pressure and organ fibrosis through local and systemic
mechanisms.57 Ang II infusion represented the simplest way
to address the question of whether C57BL/6 mice were
intrinsically resistant to CKD. We were able to confer
sensitivity upon CKD-resistant C57BL/6 mice by Ang II
infusion and 5/6 Nx, but high blood pressure alone was not
enough to cause CKD; Ang II alone did not cause CKD in
C57BL/6 mice, and CD-1 mice do not get CKD sponta-
neously. An increase in blood pressure by DOCA–salt caused
a small but significant amount of CKD after 5/6 Nx,
indicating that Ang II did not act solely through elevation
of blood pressure or aldosterone release. An angiotensin
receptor blocker olmesartan significantly reduced blood
pressure and the corresponding progression of CKD in the
CD-1 strain; however, hydralazine reduced blood pressure
without reducing CKD progression. Although these data are
consistent with a blood pressure-independent role for Ang II,
we cannot rule out blood pressure as a major component of
Ang II action. We were not able to achieve complete reversal
of hypertension; an elevated blood pressure of even a few
mmHg has a substantial effect on outcomes in proteinuric
patients.50 Our data are consistent with the current consensus
that the RAAS system, particularly Ang II, is central to CKD
progression,58 but less important for initiation. Indeed, early
administration of angiotensin-converting enzyme inhibitors
to normotensive, normalbuminuric type 1 diabetic patients
slowed retinopathy, but not nephropathy,59 and losartan may
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have caused harm. Ang II has multiple effects that can impact
the progression of CKD, including vasoconstriction, increas-
ing aldosterone release, increasing sodium retention, as well
as increasing interstitial fibrosis through transforming growth
factor-b.60,61 Pleiotropic actions of Ang II make it difficult
to distinguish between direct and indirect mechanisms, and
novel functions of Ang II are still being uncovered;62
therefore, the complexity of Ang II function requires tools
to further dissect which receptor is activated and in which
tissue and cell type it is located.31,63
A nonintrinsic role of tubulointerstitial fibrosis
Blood pressure, RAAS activation, and interstitial fibrosis are
associated with CKD progression, and they are all linked by
Ang II and transforming growth factor-b. We attempted to
dissociate interstitial fibrosis from the other two confounding
progression factors by examining if the strain-dependent
differences in blood pressure and CKD progression also
altered the propensity to develop interstitial fibrosis
(‘intrinsic fibrosis’). When we induced fibrosis without
hypertension in the folic acid, UUO, and Chr post-I/R
models, we found that there was no significant difference in
the extent of fibrosis between the three mouse strains.
Although we did not test the question directly, our data are
suggestive of a more central role for blood pressure than
tubulointerstitial fibrosis, at least in mice. Whether this
applies in humans remains an open question.
Is the strain-dependent susceptibility to 5/6 Nx-induced
CKD due to baseline characteristics?
If baseline blood pressure or intrinsic fibrosis cannot account
for the CKD resistance of the C57BL/6 strain, then what
allows CD-1 mice to be susceptible to CKD? A systemic
elevated RAAS state does not explain the difference between
baseline blood pressure of CD-1/129S3 and C57BL/6 mice, as
proposed by Ma and Fogo,22 because baseline renin levels
were not significantly different. A localized intrarenal RAAS
activation64 is one possible explanation for the differences
between strains. Non-RAAS mechanisms may also be
involved because olmesartan did not completely return
blood pressure in CD-1 (5/6 Nx mice) to control levels.
Implications for CKD
As we examined factors that could improve our mouse model
for CKD, we recognized that removal of renal mass and the
resulting loss of GFR was not enough to cause progression,
and that accelerants were essential. Therefore, monitoring
GFR during CKD is important for staging and prognosis, but
identifying CKD accelerants and their relative contribution to
progression can add an important dimension to diagnosis/
prognosis, as well as lead to more effective therapies.
The importance of Ang II as an accelerant in our CKD
model reflects the success of angiotensin-converting enzyme/
angiotensin receptor blockers clinically, but many patients
still progress despite treatment.50 A promising approach
to identifying accelerants is testing whether genetically
identified risk factors such as MYH9 (non-muscle myosin
heavy chain 9)65–68 contribute to CKD progression in animal
models. Therefore, we present a model that can delve into the
complex pathophysiology of initiation as well as progression
above and beyond Ang II, so that we can improve upon
the success of angiotensin-converting enzyme/angiotensin
receptor blocker therapy.
MATERIALS AND METHODS
Animals and animal models
Animal care followed the National Institutes of Health (NIH)
criteria for the use and treatment of laboratory animals. Male mice,
6- to 8-week-old CD-1 (Charles River Laboratories, Wilmington,
MA, USA), C57BL/6 and 129S3 (also known as 129S1/SvImJ/Cr;
NCI-DCT, Frederick, MD, USA) had free access to water and chow.
Morbidly ill animals were killed as per the animal protocol.
The 5/6 Nx was performed in two stages69 under isoflurane
anesthesia (Figure 1). At the first stage (week 1), the left kidney was
decapsulated to avoid ureter and adrenal damage, and then the
upper and lower poles were partially resected via a left flank
incision. Bleeding was controlled by microfibrillar collagen hemo-
stasis (Avitene; Davol). The upper and lower poles were weighed.
After 1 week (week 0), the entire right kidney was removed via a
right flank incision and weighed. Animals with insufficient kidney
resection (as determined by the ratio of removed left kidney
weight (at week 1) to the removed right kidney weight (at week 0)
o0.55) were killed. The mortality rate in the first week after right
nephrectomy was 10% in CD-1, 6% in 129Sv, and 9% in C57BL/6.
In preliminary studies, we found that adequate resection of the left
kidney (weight ratio between 0.55 and 0.72) in CD-1 caused
significant albuminuria at 4 weeks (trace dipstick proteinuria or
ACR 4700 mg/mg) in most of the mice (data not shown). In the
sham surgery control mice, a left flank incision was performed at
week 1, both poles of kidney were identified, and then the flank
incision was closed; a subsequent right flank incision was performed
at week 0, the right renal artery was identified, and then the flank
incision was closed. In the partial nephrectomy (2/6 Nx) control
mice, the upper and lower poles of left kidney were cut in week 1
and the right renal artery was identified at week 0. The bilateral
nephrectomy surgery in C57BL/6 for testing Ang II effectiveness was
done under isoflurane anesthesia via bilateral flank approach.
To determine strain-dependent susceptibility to kidney fibrosis,
three types of injury that do not cause hypertension were induced
in CD-1, 129S3, and C57BL/6 mice. Chr post-I/R was performed
in two stages, a modification of previously reported methods.70–72
In the first stage (week 1), the left renal artery was clamped for
35min via a left flank incision under ketamine anesthesia on a 37 1C
heated operation table. After 1 week (week 0), the right
nephrectomy was performed under isoflurane anesthesia via a right
flank incision. UUO was performed by ligation of left ureter.73 Folic
acid-induced tubulointerstitial fibrosis (FA) was performed as
previously described.19 The UUO and FA mice were killed after
2 weeks, 5/6 Nx mice were killed after 4–16 weeks, and Chr post-I/R
mice were killed 12–16 weeks after surgery.
Measurement of blood pressure
MAP was measured by radiotelemetry as previously described.19
A telemeter transmitter (model TA11PA-C10, Data Sciences
International, St Paul, MN, USA) was implanted in a subcutaneous
pocket on the left flank and the tip of the catheter was inserted into
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the aortic arch via the carotid artery 1 week before subsequent
operations (for example, week 2 of the 5/6 Nx model).
Drug administration
Val5-Ang II 0.75mg/kg/min (Sigma-Aldrich, St Louis, MO, USA) in
normal saline solution or vehicle (normal saline solution alone) was
infused by subcutaneous osmotic minipump (Alzet model 1004,
Cupertino, CA, USA). The osmotic minipump was inserted under
isoflurane anesthesia at 3 days after right Nx or sham surgery of right
Nx in 5/6 Nx experiment, and immediately after bilateral Nx. The
selective angiotensin receptor blocker olmesartan74,75 (100mg/kg) or
placebo was mixed with mouse chow (Bio-Serv, Frenchtown, NJ,
USA). Mice were started on the diet 3 days after right nephrectomy.
Alternatively, a DOCA pellet (Innovative Research of America,
Sarasota, FL, USA) (50mg per pellet for 21-day release) or placebo
was implanted subcutaneously 3 days into C57BL/6 mice after right
Nx and at the beginning of week 4 to increase blood pressure;76 all
mice were given 0.9% normal saline solution as drinking water upon
drug pellet implantation. To reduce blood pressure, hydralazine
(Sigma-Aldrich), 250mg/l, was added in the drinking water of CD-1
mice 3 days after right Nx.76
Blood chemistries, body weight, and urine measurements
At weeks 0, 1, 2, 4, 8, and 12 after surgery, 60 ml of blood was
collected by retro-orbital approach under isoflurane anesthesia and
the body weight was recorded. The following measurements were
obtained: hematocrit by the microhematocrit method with micro-
capillary reader, SCr) by high-performance liquid chromatogra-
phy,77 blood urea nitrogen by colorimetric assay (QuantiChrom
Urea assay kit DIUR-500, Hayward, CA, USA), and EPO by enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis, MN,
USA). Hematocrit measured by microhematocrit method and
Coulter Counter (Hitachi 917; Boehringer Mannheim, Indianapolis,
IN, USA) method was similar at week 4 in CD-1, week 12 in 129S3,
and week 16 in C57BL/6. Spot urine at 0900 to 1000 hours was
collected for ACR measured by enzyme-linked immunosorbent
assay (Albuwell M; Exocell, Philadelphia, PA, USA). ACR measure-
ment was confirmed by 24 h urine albumin using mouse metabolic
cages (Hatteras Instrument, Cary, NC, USA).
Blood collection and plasma renin determination
Mice were kept in separate cages overnight before starting the
experiment. Blood was collected from conscious mice by puncturing
the submandibular vessels with a Goldenrod animal lancet and
collecting about 20–40 ml of the emerging blood into an EDTA-
containing microhematocrit tube. Red cells and plasma were
separated by centrifugation for 3min at 12,000 r.p.m.; the plasma
was ejected into an Eppendorf tube and frozen until used for renin
determinations. Plasma renin concentration was measured in a 20-
fold dilution as generation of Ang I following addition of excess rat
substrate, with final plasma dilutions around 1:120. Ang I
generation was determined for a 1-h incubation period at 37 1C
and expressed as ng Ang I/ml/h. Substrate without plasma was
incubated for the same time, and any background Ang I formation
was subtracted from the plasma-containing samples by taking an
aliquot from the same sample before it was incubated at 37 1C. A
radioimmunoassay kit (DiaSorin CA1553, Stillwater, MN, USA) was
used to determine the amount of Ang I in each sample.
GFR measurement in conscious mice
The fluorescein isothiocyanate-labeled inulin clearance was used for
GFR measurement as previously described.78 Briefly, a single dose
of fluorescein isothiocyanate-inulin (3.7ml/g body weight) was
injected intravenously, and then blood samples were collected 10, 15,
35, 55, and 75min later from the tail vein. Serum fluorescence was
measured by a Nanodrop-ND-3300 fluorescence spectrometer
(Nanodrop Technologies, Wilmington, DE, USA). GFR was
calculated using a two compartment model (SigmaStat 3.1; Systat
Software, Richmond, CA, USA) as previously described.78
Morphologic evaluation of kidney and heart
Kidney and heart specimens (4mm) were fixed in 10% formalin,
paraffin embedded, and stained with Masson’s trichrome and PAS
reagent (Sigma-Aldrich). Semiqualitiative histological changes
were assessed by a masked observer. The total numbers of kidney
glomeruli were counted, and the degree of glomerular damage was
estimated at  400 magnification from the degree of mesangial
expansion in periodic acid-Schiff-stained tissue as follow: o25,
25–50, 50–80, and480%.79 Kidney interstitial fibrosis was estimated
at  200 magnification on Masson’s trichrome-stained sections
using 10 randomly selected fields for each animal by the following
semiquantitative criteria: 0, area of damage o5%; 1, areas of
damage 5–10%; 2, damage involving 10–25%; 3, damage involving
25–50%; and 4, 450% of the area being affected.73 The cardiac
fibrosis area was determined at  200 magnification in Masson’s
trichrome-stained sections using ImageJ 1.36b (National Institutes
of Health, Bethesda, MD, USA).
MicroCT imaging
The formalin-fixed kidney specimens were sent to Numira
Biosciences (Salt Lake City, UT, USA) for microCT-based Virtual
Histology (microCT), a submicron resolution imaging that can be
differentially stained using heavy metal elements and explore several
aspect of tissue without actually destroying tissue specimens to
achieve physiological distinction in a three-dimensional data of
structures in different directions.80 Specimens were stained with a
proprietary contrast agent. A high-resolution, volumetric microCT
scanner (mCT40 ScanCo Medical, Zurich, Switzerland) was used to
scan the tissue with the following parameters: 6 mm isometric voxel
resolution at 200ms exposure time, 2000 views, and 10 frames
per view. The microCT images were visualized using Teem (http://
teem.sourceforge.net/) and SCIRun (Scientific and Computing
Imaging Institute, University of Utah, Salt Lake City, UT, USA)
for false-color image processing to generate a three-dimensional
reconstruction of volume rendering (VR: red color) and spinning
sagittal sections (DS: blue-green color) picture.
Statistical analysis
Differences between the groups were examined for statistical signi-
ficance by Student’s t-test or analysis of variance with an appropriate
multiple comparison correction (SigmaStat 3.1, Systat Software);
longitudinal blood pressure measurements were analyzed by
repeated measures analysis of variance to test time- and strain-
dependent interactions (SAS, Cary, NC, USA). A P-value of o0.05
was accepted as statistically significant.
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